{"organizations": [], "uuid": "71b84dda176addaf80813d81d1b3b5c02136356f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180205.html", "section_title": "Archive News &amp; Video for Monday, 05 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-sorrentos-and-yuhans-joint-venture/brief-sorrentos-and-yuhans-joint-venture-immuneoncia-receives-approval-idUSASB0C3XB", "country": "US", "domain_rank": 408, "title": "BRIEF-Sorrento's And Yuhan's Joint Venture, Immuneoncia, Receives Approval", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.981, "site_type": "news", "published": "2018-02-05T21:24:00.000+02:00", "replies_count": 0, "uuid": "71b84dda176addaf80813d81d1b3b5c02136356f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-sorrentos-and-yuhans-joint-venture/brief-sorrentos-and-yuhans-joint-venture-immuneoncia-receives-approval-idUSASB0C3XB", "ord_in_thread": 0, "title": "BRIEF-Sorrento's And Yuhan's Joint Venture, Immuneoncia, Receives Approval", "locations": [], "entities": {"persons": [{"name": "yuhan", "sentiment": "negative"}, {"name": "sorrento", "sentiment": "none"}], "locations": [{"name": "immuneoncia", "sentiment": "none"}, {"name": "immuneoncia", "sentiment": "none"}, {"name": "south korea", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "joint venture", "sentiment": "negative"}, {"name": "sorrento therapeutics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 5 (Reuters) - Sorrento Therapeutics Inc:\n* SORRENTO‘S AND YUHAN‘S JOINT VENTURE, IMMUNEONCIA, RECEIVES APPROVAL TO BEGIN CLINICAL TRIAL OF ANTI-PD-L1 MONOCLONAL ANTIBODY IN SOUTH KOREA\n* SORRENTO - SOUTH KOREAN MINISTRY FOR FOOD AND DRUG SAFETY HAS APPROVED IMMUNEONCIA THERAPEUTICS’ IND FOR INITIATION OF CLINICAL TRIALS FOR STI-A1015 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-05T21:24:00.000+02:00", "crawled": "2018-02-06T23:59:07.003+02:00", "highlightTitle": ""}